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higher in RA patients suggesting a possible influence of the 
underlying disease.
Trial registration number: DRKS00004940.
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Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are 
some of the most commonly prescribed drugs all over the 
world [1]. Their use can be limited by adverse side effects 
to the gastrointestinal tract. NSAID-induced small intesti-
nal injury was underestimated in the past because of lack 
of suitable diagnostic tools. Recently, NSAID-induced 
enteropathy has paid more attention to this issue owing 
to wireless capsule and deep enteroscopy being available 
[2].
NSAID-induced enteropathy might be asymptomatic 
or can be presented with increased small intestinal perme-
ability, bleeding, erosions, ulcers, bowel perforation, dia-
phragm-like strictures, and/or jejunal and ileal dysfunction.
Wireless capsule endoscopy is a useful method for non-
invasive diagnosis of enteropathy. Small bowel lesions 
were revealed in 26–88 % COX non-selective and 6–50 % 
COX-2 selective NSAID users [3–8].
Objective
 The goal of this prospective study was to assess NSAID-
induced enteropathy in RA or OA by means of non-inva-
sive wireless capsule enteroscopy.
Abstract  The goal of this prospective study was to assess 
non-steroidal anti-inflammatory drug (NSAID)-induced 
enteropathy in patients with rheumatoid arthritis (RA) or 
osteoarthritis (OA) by means of non-invasive wireless cap-
sule enteroscopy. A total of 143 patients (74 with RA, 69 
with OA) treated with NSAIDs (>1 month) and 42 healthy 
volunteers were included. All subjects underwent capsule 
endoscopy, laboratory tests and filled in questionnaires. 
The severity of small bowel injury was graded as: mild 
(red spots or sporadic erosions), moderate (10–20 ero-
sions) or severe (>20 erosions or ulcers). Capsule endos-
copy identified small bowel lesions in 44.8 % of patients 
(mild 36.4 %, moderate 3.5 % and severe in 4.9 %). Mild 
non-specific lesions were found in 11.9 % healthy volun-
teers. There was a significantly higher prevalence of enter-
opathy in RA (56.8 %) compared to OA (31.9 %, p < 0.01). 
A significant difference between NSAID users (RA and 
OA) with and without enteropathy was observed in eryth-
rocytes (p < 0.01), the leucocyte count (p < 0.05), haemo-
globin (p < 0.05), haematocrit (p < 0.05), serum albumin 
(p < 0.01) and erythrocyte sedimentation rate (p < 0.05). No 
relationship was found between enteropathy and dyspepsia, 
gender or age. NSAID therapy is associated with a sig-
nificant risk of small bowel injury. The risk is significantly 
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The project was designed as a prospective and 
endoscopist-blinded study. Inclusion criteria comprised 
adult patients (>18 years) treated for RA or OA by 
NSAIDs (>1 month) and adult healthy volunteers with-
out any medical therapy. RA fulfilled the 1987 criteria of 
the American College of Rheumatology [9]. OA was con-
firmed by X-ray.
Exclusion criteria were gastro-oesophageal reflux dis-
ease, peptic ulcer disease, all known small bowel diseases, 
including inflammatory bowel disease and pregnancy.
A total of 143 NSAID users in RA (74 patients, 57 
women, mean age 52, median 53 years) or OA (69 
patients, 44 women, mean age 67, median 67 years) and 
42 control healthy volunteers (29 women, mean age 43, 
median 42 years) were enrolled. All patients underwent 
capsule endoscopy, completed a questionnaire focused 
on history and clinical data, and laboratory tests (blood 
count, Coombs test, iron-binding capacity, serum iron, 
ferritin, albumin, prealbumin, C-reactive protein and 
erythrocyte sedimentation rate). Stools were tested for 
the Helicobacter pylori antigen and for faecal occult 
bleeding.
Capsule endoscopy
A wireless capsule endoscopy system was used (Endo-
Capsule, Olympus) after 12-h fasting. Fluids were allowed 
2 h after ingestion of the capsule endoscope, followed by 
a light meal 4 h later. Capsule position was verified 2 h 
after ingestion by means of a real-time viewer. Gastros-
copy-assisted insertion of the capsule endoscope through 
the pylorus was performed in three cases of capsule per-
sistence in the stomach. The capsule endoscopy investiga-
tor (I.T.) was experienced in enteroscopy and blinded to all 
data.
Type and localisation of small bowel lesions, other 
abnormal findings and transit times were evaluated. Endos-
copy findings were described as red spots (reddish area 
of mucosa), erosions (superficial destruction of mucosa), 
denuded areas (mucosal surface without villi), aphthous 
lesions (a mucosal break with a pale centre and reddish 
halo) and ulcers (a local defect in lining or excavation of 
the mucosa surface with its base covered with fibrin). Find-
ings were classified into three grades as mild (multiple red 
spots or <10 erosions and/or aphthous lesions), moderate 
(10–20 erosions or aphthous lesions) and severe (>20 ero-
sions or aphthous lesions, ulcers, stenosis and/or bleeding). 
Localisation of lesions was roughly estimated according 
to transit time and actual capsule position on the screen of 
computer workstation. Small intestinal visibility in differ-
ent segments of the bowel was scored.
Statistics
Qualitative data were compared using contingency tables, a 
Chi-squared test for independence and Goodman–Kruskal 
gamma test for trend evaluation. We used two-sample t test, 
Mann–Whitney test, one-factor analysis of variance and 
Kruskal–Wallis test. Testing was performed on a signifi-
cance level of 5 %.
Results
Endoscopy findings
All participants underwent capsule endoscopy without any 
complications. Complete small bowel investigation was 
performed in 99 % of all procedures in NSAID users and in 
all healthy volunteers. Excellent small bowel visibility was 
achieved in 142 of 185 (77 %) capsule endoscopies; there 
was some bowel content in the distal ileum in 43/185 (23 %).
NSAID-induced enteropathy was observed in 64/143 
NSAID users (44.8 %). Mild non-specific findings (spo-
radic red spots) were identified in 5 (11.9 %) healthy vol-
unteers (p < 0.001). A statistically significant difference 
between the RA and OA was identified in the prevalence 
(56.8 vs. 31.9 %, p < 0.01) and severity of enteropathy 
(p < 0.01). The small intestinal findings observed included 
red spots or mucosal erythema, erosions, aphthous lesions 
and ulcers (Fig. 1). No strictures, bleeding or denuded areas 
were revealed. Other small intestinal findings, not associ-
ated with NSAIDs, were: lymphangiectasias, phlebectasias, 
xanthomas and lipoma. NSAID-induced gastropathy was 
observed in 33.8 % RA and 21.7 % OA.
There was no difference in gastric emptying time and 
small bowel transit time in NSAID users according to the 
presence and severity of enteropathy (data not displayed).
Clinical data
In the RA group, the mean age of RA diagnosis was 
42 years. Rheumatoid factors were positive in 54 cases 
(73 %), and RA was classified as grade I (according to 
Steinbrocker’s classification) in 5, grade II in 29, grade III 
in 31 and grade IV in nine patients. The average disease 
activity score (DAS 28) was 3.46 ± 1.49 (median 3.28). No 
statistically significant difference in the DAS 28 score and 
RA grading according to presence and the severity of iden-
tified enteropathy was observed.
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All patients were treated with NSAIDs, most for sev-
eral years: >1 year 70 (95 %) RA and 62 (90 %) OA. 
There was no difference in the prevalence of identified 
enteropathy in the context of COX selectivity or duration 
of use of NSAIDs, DAS 28 score and/or age and gender 
and/or either in RA or OA (data not displayed). NSAID 
users with concomitant acetylsalicylic acid or systemic 
glucocorticoid therapy had a higher rate of enteropathy 
in comparison with the remaining patients (p = 0.029, 
p = 0.003). Other medical treatment (e.g. biologic ther-
apy, disease-modifying antirheumatic drugs, proton pump 
inhibitors, warfarin, bisphosphonates and others) did not 
influence the prevalence of enteropathy identified by cap-
sule enteroscopy.
Dyspepsia, defined as any type of abdominal discomfort, 
including nausea, vomiting, abdominal fullness, pain, con-
stipation and/or diarrhoea, was identified in 28 (38 %) RA 
and in 52 (75 %) OA (p < 0.01).
Laboratory tests
A statistically significant difference between patients 
with and without enteropathy was found in erythro-
cytes (p = 0.002), haemoglobin (p = 0.015), haematocrit 
(p = 0.044), leucocytes (p = 0.023), erythrocyte sedimen-
tation rate after 1 h (p = 0.036), serum albumin (p = 0.007) 
and positive faecal occult blood test (p = 0.010). There 
was no difference in Helicobacter pylori prevalence (20 
patients, 14 %). Anaemia was more common in RA (31 
patients; 42 %) compared to OA (4; 6 %).
Discussion
Our study found a high prevalence of enteropathy in 
chronic NSAID users and provided important new original 
data. Capsule endoscopy identified small intestinal lesions 
Fig. 1  NSAID-induced enteropathy grading. a mild grade: red spot in jejunum, b moderate grade: multiple erosions in distal jejunum, c severe 
grade: ulceration in ileum, d severe grade: jejunal ulcer
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in 44.8 % patients, but only a few lesions were assessed as 
moderate (3.5 %) or severe (4.9 %). That is much less than 
previously reported [7, 8, 10].
The most important finding was a significantly higher 
prevalence and severity of enteropathy in RA patients com-
pared to OA. The influence of principal immunopathology, 
playing a crucial role in RA, might be a possible explana-
tion. Similarly, the prospective data from the arthritis, rheu-
matism and ageing medical information system (ARAMIS) 
showed a higher risk of serious gastrointestinal complica-
tions of NSAIDs in RA when compared to OA (13 vs. 7.3 
per 1000 patients per year) [11–13]. We are fully aware of 
the possible limits; thus, our findings must be interpreted 
with caution. Numbers of patients in our study are relatively 
low. There are other possible confounding factors such as 
different types and daily and cumulative doses of NSAID.
Although lower prevalence of small intestinal damage in 
COX-2 selective NSAID users was repeatedly demonstrated 
in comparison with non-selective NSAID users [3], we did 
not observe this phenomenon in our study. An explanation 
for this may be the relatively low proportion of COX-2 
selective NSAID users (RA 13 %, OA 9 %) and other 
mechanisms of small bowel toxicity (chemical structure 
and local effect, metabolism, rates of enterohepatic circula-
tion, etc). We proved a higher risk of enteropathy in patients 
with concomitant acetylsalicylic acid and/or glucocorticoids 
(but not with other medical therapy). A substantial number 
of our patients were also treated with proton pump inhibi-
tors (80 % RA, 35 % OA). Recent studies found that pro-
ton pump inhibitors can exacerbate NSAID-induced small 
intestinal injury by inducing bacterial dysbiosis of the small 
bowel [14, 15]. We were not able to confirm these findings.
Surprisingly, mild non-specific mucosal changes at cap-
sule endoscopy were also found in 12 % of the healthy 
volunteers. All of our control subjects were healthcare pro-
fessionals at our University Hospital, available for a sub-
sequent 3-year follow-up. All remained clinically healthy, 
symptom-free and developed no illness. Similar findings of 
mild mucosal changes during capsule endoscopy were also 
found in 7–41 % of control subjects in other previously 
published studies [3–5, 10]. It is necessary to emphasise 
this fact and to interpret these mild non-specific findings 
(like sporadic red spots) with caution.
Dyspepsia was significantly more frequently recorded 
in OA (75 %) compared with RA (38 %) in our study, but 
there was no association with small intestinal findings dur-
ing capsule endoscopy.
Conclusions
Wireless capsule enteroscopy is an important non-inva-
sive diagnostic tool to diagnose NSAID-induced injury 
to the small bowel. Small intestinal lesions were identi-
fied in 44.8 % of patients in our current study, mostly 
mild (36.4 %), less frequently moderate (3.5 %) or severe 
(4.9 %). These lesions were more frequently found in RA 
(56.8 %) compared to OA (31.9 %). No laboratory marker 
and/or clinical data can be used as a diagnostic or prognos-
tic factor.
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